[
  {
    "ts": "2026-01-22T00:25:28+00:00",
    "headline": "Is Bullish CF Analyst Sentiment Reframing the Pipeline Risk Narrative for Vertex Pharmaceuticals (VRTX)?",
    "summary": "In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, both citing confidence in the company’s core cystic fibrosis business and upcoming clinical data readouts in 2026–2027. This cluster of positive analyst views has sharpened investor focus on how Vertex’s cystic fibrosis franchise underpins its broader pipeline ambitions and risk profile. We’ll now look at how this wave of bullish analyst commentary around Vertex’s cystic...",
    "url": "https://finance.yahoo.com/news/bullish-cf-analyst-sentiment-reframing-002528202.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5a7f1b02-50df-32c7-a0af-ac9e8e04cc57",
      "content": {
        "id": "5a7f1b02-50df-32c7-a0af-ac9e8e04cc57",
        "contentType": "STORY",
        "title": "Is Bullish CF Analyst Sentiment Reframing the Pipeline Risk Narrative for Vertex Pharmaceuticals (VRTX)?",
        "description": "",
        "summary": "In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, both citing confidence in the company’s core cystic fibrosis business and upcoming clinical data readouts in 2026–2027. This cluster of positive analyst views has sharpened investor focus on how Vertex’s cystic fibrosis franchise underpins its broader pipeline ambitions and risk profile. We’ll now look at how this wave of bullish analyst commentary around Vertex’s cystic...",
        "pubDate": "2026-01-22T00:25:28Z",
        "displayTime": "2026-01-22T00:25:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bullish-cf-analyst-sentiment-reframing-002528202.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bullish-cf-analyst-sentiment-reframing-002528202.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "UBS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-22T16:17:57+00:00",
    "headline": "Vertex Pharmaceuticals Poised for Higher Valuation on Povetacicept, Cystic Fibrosis Pipeline, RBC Says",
    "summary": "Vertex Pharmaceuticals' (VRTX) near-term data cementing the bright prospects of investigational drug",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-poised-higher-valuation-161757484.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "b1c13a12-7f21-32a2-84e6-86a424bbfe9f",
      "content": {
        "id": "b1c13a12-7f21-32a2-84e6-86a424bbfe9f",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Poised for Higher Valuation on Povetacicept, Cystic Fibrosis Pipeline, RBC Says",
        "description": "",
        "summary": "Vertex Pharmaceuticals' (VRTX) near-term data cementing the bright prospects of investigational drug",
        "pubDate": "2026-01-22T16:17:57Z",
        "displayTime": "2026-01-22T16:17:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-poised-higher-valuation-161757484.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-poised-higher-valuation-161757484.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]